Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Research on the links between tenofovir and other antiretrovirals, SARS-CoV-2 infection and COVID severity has produced mixed results.
People with suppressed HIV respond well to mRNA vaccines, but individuals with a low CD4 count may not be adequately protected.
The good news is that only 4% of HIV-positive people experienced COVID breakthrough after vaccination.
After falling off early in the pandemic, viral suppression at San Francisco’s Ward 86 clinic recovered with intensified services.
Molnupiravir, the first oral antiviral for COVID-19, reduces the risk of hospitalization or death if started within five days.
Pioneering HIV doctor Paul Volberding and veteran activist Gregg Gonsalves reflect on the legacy of AIDS and its implications for COVID-19.
The COVID-19 pandemic has profoundly disrupted almost every aspect of the battle against HIV.
At the current pace, only about 20% of the world’s population will be vaccinated by the end of 2021.
The HIV protease inhibitor combination did not speed recovery or reduce the risk of death in a large study.
People living with HIV are learning how to cope with a new pandemic.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.